The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
177Lu-PSMA radioligand therapy for patients with recurrent/metastatic (R/M) salivary gland cancer (SGC): A phase II pilot study.
 
Carla M.L.- Van Herpen
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Ipsen (Inst); MSD (Inst); Regeneron (Inst)
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Sanofi Aventis GmbH (Inst)
 
Maike Uijen
No Relationships to Disclose
 
Niels van Ruitenbeek
No Relationships to Disclose
 
Chantal M.L. Driessen
No Relationships to Disclose
 
Martin Gotthardt
Research Funding - Pentixapharm (Inst)
 
James Nagarajah
Consulting or Advisory Role - POINT Biopharma (Inst)
Speakers' Bureau - Bayer (Inst); Pfizer (Inst)
Research Funding - Novartis (Inst)